Clinical Trials
12 trialsNCT04430894 2026-06-03
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06203912 2026-05-26
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05911321 2026-05-20
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03104842 2026-05-15
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Active not recruiting
NCT05669989 2026-05-11
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03319667 2026-05-04
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT04653246 2026-04-30
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02960555 2026-04-15
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05873205 2026-04-02
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04835129 2026-03-27
IMPEDE
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting